Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
January 4, 2019 - The FDA announced the discontinuation of Bristol Myers Squibb’s Daklinza (daclatasvir) 30 mg and 60 mg tablets.
Download PDF
Return to publications
